Application | Comment | Organism |
---|---|---|
medicine | the prevalence of dihydrofolate reductase 19-bp deletion polymorphism and of the methylenetetrahydrofolate reductase C677T polymorphism is similar in cancer patients with and without thrombosis. The frequency of factor V Leiden polymorphism is significantly higher in cancer patients with thrombosis. Thus routine screening for dihydrofolate reductase 19-bp deletion polymorphism is not suggested | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
cancer patients with and without thrombosis | - |